Nora Hutchinson, MD
Assistant Professor
Medicine
School of Medicine

Education & Training

Show all (5) Hide

• Internal Medicine Fellowship Training McGill University 06/2019
• Internal Medicine Residency Training Alpert Medical School, Brown University, Rhode Island Hospital 06/2017
• MPhil History and Philosophy of Science, Technology and Medicine Cambridge University 07/2013
• M.D.,C.M. Doctor of Medicine McGill University 05/2012
• BA First Class Honors in History and First Class Honors in Anthropology McGill University 05/2006

Interests

Show all (3) Hide

• Research Ethics
• Meta-Research
• Clinical Trials

Publications (13)

Top publication keywords:
Clinical Trials as TopicEthics, MedicalBiological ProductsPatient ParticipationNeoplasmsResearch DesignDrug ApprovalDrugs, InvestigationalTruth DisclosureRandomized Controlled Trials as TopicUnited States Food and Drug AdministrationAntineoplastic AgentsAntiviral AgentsPatient SelectionClinical Trials, Phase I as Topic

• Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies.
  JCO oncology practice 2023 Hutchinson N, Bicer S, Feldhake E, Carlisle BG, Gonen M, Del Paggio J, Kimmelman J
• Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study.
  Scientific reports 2023 Ouimet C, Hutchinson N, Wang C, Matyka C, Del Paggio JC, Kimmelman J
• Timing for First-in-Minor Clinical Trials of New Cancer Drugs.
  The Journal of pediatrics 2023 Bicer S, Hutchinson N, Feldhake E, Nelson A, Oliviero E, Waligóra M, Kimmelman J
• How to limit uninformative trials: Results from a Delphi working group.
  Med (New York, N.Y.) 2023 Gelinas L, Hutchinson N, Zarin DA, Bierer BE
• Disclosure of Possible Trial Termination to Participants of Interventional Clinical Trials.
  JAMA 2023 Hutchinson N, Gelinas L, Zarin D, Bierer BE

Show all (8 more) Hide

• Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis.
  BMC research notes 2022 Hutchinson N, Klas K, Carlisle BG, Polak M, Kimmelman J, Waligora M
• The proportion of randomized controlled trials that inform clinical practice.
  eLife 2022 Hutchinson N, Moyer H, Zarin DA, Kimmelman J
• Quantifying Patient Investment in Novel Neurological Drug Development.
  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022 MacPherson A, Gumnit E, Ouimet C, Hutchinson N, Kieburtz K, Pearson TS, Kimmelman J
• How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov.
  PloS one 2022 Hutchinson N, Klas K, Carlisle BG, Kimmelman J, Waligora M
• Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
  JAMA network open 2021 Hutchinson N, Carlisle B, Doussau A, Bosan R, Gumnit E, MacPherson A, Fergusson DA, Kimmelman J
• Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.
  Annals of internal medicine 2020 MacPherson A, Hutchinson N, Schneider O, Oliviero E, Feldhake E, Ouimet C, Sheng J, Awan F, Wang C, Papenburg J, Basta NE, Kimmelman J
• The proportion of North American cancer trials that evaluate novel targets.
  Investigational new drugs 2020 Gumnit E, Feustel AC, Wong S, Bosan R, Hutchinson N, Kimmelman J
• Ethical and Policy Issues for Seamless Phase I Oncology Trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Hutchinson N, Vinarov E, Iasonos A, Kimmelman J